ARDX
ARDELYX, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.09
+0.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.09
From 52W high−61.33%
Volume3.23M
Market cap$797.80M
P/E (TTM)—
P/S (TTM)1.8x
Div yield—
Key dataOct 19, 2026
Open
$3.09
From 52W high
−61.33%
Volume
3.23M
Market cap
$797.80M
ValuationView details →
P/E (Fwd)
44.3x
EV/EBITDA
−31.3x
P/E (TTM)
—
RSI (14)
32.0
MomentumView details →
1D Return
+0.00%
YTD Return
−46.83%
SummaryUpdated Jun 1, 2026
Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company founded in 2007 and headquartered in Waltham, Massachusetts. Originally incorporated as Nteryx, Inc., the company changed its name to Ardelyx in June 2008 and went public in 2014. Ardelyx has evolved from a development-stage biotechnology company into a commercial-stage organization with two FDA-approved products addressing unmet medical needs in gastrointestinal and kidney-related conditions. The company has successfully transitioned from years of research and development losses to achieving profitability in 2024, marking a significant milestone in its corporate evolution.
Similar companies
Latest newsMore news →
A class action lawsuit was filed against Ardelyx on behalf of investors who acquired its common stock during the stated class period.6d agoArdelyx announced real-world analysis results showing significantly reduced gastrointestinal-related healthcare resource utilization after adults with IBS-C initiated IBSRELA.8d agoGrabar Law Office announced an investigation into whether certain officers and directors of Ardelyx, Inc. breached their fiduciary duties owed to the company and its shareholders.19d ago